Study Leader for the Mechanism of Tumor Cell Apoptosis
| Academician Mr. Jiang Jiandong Academician of Chinese Academy of Engineering Director of Institue of Materia Medica Chinese Academy of Medical Sciences Researcher, Doctoral Tutor Mainly engaged in antiviral, antimetabolic disease and anti-tumor new drug research. From 1989 to 1999, he worked at Mount Sinai School of Medicine at NYU. After returning to China, he worked at Institute of Medical Biotechnology, Chinese Academy of Medical Sciences. He has successively been a researcher, doctoral tutor, assistant director, vice director and director. In December 2010, he was appointed director of Institute of Materia Medica, Chinese Academy of Medical Sciences. In 2012, he became the first president of Medicine Research Academy, Chinese Academy of Medical Science, which is composed of Institue of Materia Medica, Institute of Medical Biotechnology and Institute of Medicinal Plant Development. In 2021, he was elected as an academician of the Chinese Academy of Engineering in 2021 (Department of Medicine and Health) He is currently editor-in-chief of Acta Pharmaceutica Sinica B and member of the Academic Degrees Committee of the State Council. Part-time: Vice President of China Pharmaceutical industry Research and Development Association; Managing Director of Chinese Pharmacological Society. |
Director of Study on Immune Antitumor Mechanisms
| Dr. CHEN Xiaoguang Researcher, Doctor Tutor Mainly engaged in anti-tumor drug molecular pharmacology research, new drug creation and development, research and development of Immunomodulatory Agents. Committee member of China Anti-Cancer Association Vice director of the Committee on Molecular and Biochemical Pharmacology, Chinese Pharmacological Society Vice director of the Committee on Anti-tumor Drugs, Chinese Pharmaceutical Association Member of the Committee of Marine Drugs, Chinese Pharmaceutical Association Director of the Committee of Applied Pharmacology, Beijing Pharmaceutical Association Assessment expert of “11th-Five-Year Plan” and “12th-Five-Year Plan” for major new drug creation project of Ministry of Science and Technology of the People's Republic of China CFDA (China Food and Drug Administration) New Drug Assessment Expert Bank Member, CFDA Health Product Assessment Expert Assessment Expert of New Pharmaceutical Project of Beijing Pharma and Biotech Center Member of the academic degree evaluation committee of Institute of Materia Medica, Chinese Academy of Medical Sciences Member of the Academic Committee of the Institute of Institute of Materia Medica, Chinese Academy of Medical Sciences Editorial Board Member of Chinese Journal of Oncology In 2004, she was awarded the first group of national-level candidates for the new century's millions of talents project. |
